Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models

Lung cancer is the leading cause of cancer mortality worldwide (1). Although the incidence rate of lung cancer in women is lower than that of breast cancer, the 5-year survival rate for lung cancer is less than 20% in North America and other developed countries, thereby making it the leading cause of cancer mortality among women (2,3).